AIM: To assess the prevalence of advanced liver fibrosis (ALF) in human immunodeficiency virus (HIV), hepatitis C virus (HCV) and HIV/HCV patients using transient elastography, and to identify factors associated with ALF. METHODS: Between September 2008 and October 2009, 71 HIV mono-infected, 57 HIV/HCV co-infected and 53 HCV mono-infected patients on regular follow-up at our Center were enrolled in this study. Alcohol intake, the main parameters of liver function, presence of HCV-RNA, HIV-RNA, duration of highly active anti-retroviral therapy (HAART) and CD4 cell count were recorded. ALF was defined as liver stiffness (LS) ≥ 9.5 kPa. To estimate liver fibrosis (LF) a further 2 reliable biochemical scores, aspartate aminotransferase platelet ratio index (APRI) and FIB-4, were also used. RESULTS: LS values of co-infected patients were higher than in either HIV or HCV mono-infected patients (χ(2)(MH) = 4, P < 0.04). In fact, LS ≥ 9.5 was significantly higher in co-infected than in HIV and HCV mono-infected patients (χ(2) = 5, P < 0.03). Also APRI and the FIB-4 index showed more LF in co-infected than in HIV mono-infected patients (P < 0.0001), but not in HCV mono-infected patients. In HIV⁄HCV co-infected patients, the extent of LS was significantly associated with alcohol intake (P < 0.04) and lower CD4+ cell count (P < 0.02). In HCV patients, LS was correlated with alcohol intake (P < 0.001) and cholesterol levels (P < 0.03). Body mass index, diabetes, HCV- and HIV-viremia were not significantly correlated with LS. In addition, 20% of co-infected patients had virologically unsuccessful HAART; in 50% compliance was low, CD4+ levels were < 400 cells/mm(3) and LS was > 9.5 kPa. There was no significant correlation between extent of LF and HAART exposure or duration of HAART exposure, in particular with specific dideoxynucleoside analogues. CONCLUSION: ALF was more frequent in co-infected than mono-infected patients. This result correlated with lower CD4 levels. Protective immunological effects of HAART on LF progression outweigh its hepatotoxic effects.
AIM: To assess the prevalence of advanced liver fibrosis (ALF) in human immunodeficiency virus (HIV), hepatitis C virus (HCV) and HIV/HCVpatients using transient elastography, and to identify factors associated with ALF. METHODS: Between September 2008 and October 2009, 71 HIV mono-infected, 57 HIV/HCV co-infected and 53 HCV mono-infected patients on regular follow-up at our Center were enrolled in this study. Alcohol intake, the main parameters of liver function, presence of HCV-RNA, HIV-RNA, duration of highly active anti-retroviral therapy (HAART) and CD4 cell count were recorded. ALF was defined as liver stiffness (LS) ≥ 9.5 kPa. To estimate liver fibrosis (LF) a further 2 reliable biochemical scores, aspartate aminotransferase platelet ratio index (APRI) and FIB-4, were also used. RESULTS: LS values of co-infected patients were higher than in either HIV or HCV mono-infected patients (χ(2)(MH) = 4, P < 0.04). In fact, LS ≥ 9.5 was significantly higher in co-infected than in HIV and HCV mono-infected patients (χ(2) = 5, P < 0.03). Also APRI and the FIB-4 index showed more LF in co-infected than in HIV mono-infectedpatients (P < 0.0001), but not in HCV mono-infected patients. In HIV⁄HCV co-infected patients, the extent of LS was significantly associated with alcohol intake (P < 0.04) and lower CD4+ cell count (P < 0.02). In HCVpatients, LS was correlated with alcohol intake (P < 0.001) and cholesterol levels (P < 0.03). Body mass index, diabetes, HCV- and HIV-viremia were not significantly correlated with LS. In addition, 20% of co-infected patients had virologically unsuccessful HAART; in 50% compliance was low, CD4+ levels were < 400 cells/mm(3) and LS was > 9.5 kPa. There was no significant correlation between extent of LF and HAART exposure or duration of HAART exposure, in particular with specific dideoxynucleoside analogues. CONCLUSION:ALF was more frequent in co-infected than mono-infected patients. This result correlated with lower CD4 levels. Protective immunological effects of HAART on LF progression outweigh its hepatotoxic effects.
Authors: J Poniachik; D E Bernstein; K R Reddy; L J Jeffers; M E Coelho-Little; F Civantos; E R Schiff Journal: Gastrointest Endosc Date: 1996-06 Impact factor: 9.427
Authors: G Montalto; M Soresi; A Carroccio; F Bascone; S Tripi; F Aragona; G Di Gaetano; A Notarbartolo Journal: Digestion Date: 2001 Impact factor: 3.216
Authors: F Blanco; P Barreiro; P Ryan; E Vispo; L Martín-Carbonero; P Tuma; P Labarga; J Medrano; J González-Lahoz; V Soriano Journal: J Viral Hepat Date: 2011-01 Impact factor: 3.728
Authors: Luz Martín-Carbonero; Yves Benhamou; Massimo Puoti; Juan Berenguer; José Mallolas; Carmen Quereda; Ana Arizcorreta; Antonio Gonzalez; Jurgen Rockstroh; Victor Asensi; Pilar Miralles; Montse Laguno; Leonor Moreno; José Antonio Girón; Martin Vogel; Javier García-Samaniego; Marina Nuñez; Miriam Romero; Santiago Moreno; Juan José de la Cruz; Vincent Soriano Journal: Clin Infect Dis Date: 2003-12-08 Impact factor: 9.079
Authors: Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok Journal: Hepatology Date: 2003-08 Impact factor: 17.425
Authors: Carmen Martinez-Sierra; Ana Arizcorreta; Fernando Díaz; Rafael Roldán; Leopoldo Martín-Herrera; Eugenio Pérez-Guzmán; José A Girón-González Journal: Clin Infect Dis Date: 2003-01-31 Impact factor: 9.079
Authors: A H Mohsen; P J Easterbrook; C Taylor; B Portmann; R Kulasegaram; S Murad; M Wiselka; S Norris Journal: Gut Date: 2003-07 Impact factor: 23.059
Authors: Flavia F Fernandes; Hugo Perazzo; Luiz E Andrade; Alessandra Dellavance; Carlos Terra; Gustavo Pereira; João L Pereira; Frederico Campos; Maria L Ferraz; Renata M Perez Journal: Biomed Res Int Date: 2017-09-13 Impact factor: 3.411
Authors: Sang Hoon Han; Seung Up Kim; Chang Oh Kim; Su Jin Jeong; Jun Yong Park; Jun Yong Choi; Do Young Kim; Sang Hoon Ahn; Young Goo Song; Kwang-Hyub Han; June Myung Kim Journal: PLoS One Date: 2013-01-03 Impact factor: 3.240
Authors: Emanuele Focà; Massimiliano Fabbiani; Mattia Prosperi; Eugenia Quiros Roldan; Francesco Castelli; Franco Maggiolo; Elisa Di Filippo; Simona Di Giambenedetto; Roberta Gagliardini; Annalisa Saracino; Massimo Di Pietro; Andrea Gori; Laura Sighinolfi; Angelo Pan; Maria Concetta Postorino; Carlo Torti Journal: Medicine (Baltimore) Date: 2016-07 Impact factor: 1.889